医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Thailand-based SCG Acquires Stake in Liechtenstein-Based Research Company Lysando AG

2014年11月12日 PM11:00
このエントリーをはてなブックマークに追加


 

TRIESENBERG, Liechtenstein

The Siam Cement Group (SCG), headquartered in Bangkok, Thailand, one of Asia’s largest industrial conglomerates has acquired a 20 percent stake in Lysando AG, based in Balzers, Liechtenstein. The research enterprise attracted worldwide attention through its development of the innovative technology platform Artilysin®.

An international team of researchers at the privately-financed research company Lysando AG is dedicated to researching anti-microbial synthetic designer proteins, and has already developed a diverse range of Artilysin®s. This new platform paves the way for the development of products specifically engineered to combat gram-negative and gram-positive bacteria, including antibiotic-resistant and persistent bacteria. Artilysin®s represent a breakthrough in the battle against multi-resistant bacteria.

“Artilysin®s offers great potential from its application standpoints, some of which are related to SCG’s business application focus, such as food packaging, medical device, and home hygiene applications. The business model of Lysando AG is intelligent and pioneering with secured technology’s intrinsic value through numerous patents. We are impressed by the technology platform provided by Artilysin®s and Lysando AG’s portfolio of renowned customers. Following an intensive due diligence process, we have chosen to acquire a strategic stake of 20 percent in the company.” explains Chaovalit Ekabut, SCG’s Vice President – Finance and Investment & CFO.

“We are honored and proud that SCG has chosen to invest in Lysando AG, and warmly welcome our new shareholder. In taking this step, we deliberately selected a non-pharmaceutical company as it allows us to continue to license our antibiotics substitute platform unhindered by restrictions from disinfection up to human pharma. SCG recognizes the societal and economic importance of Artilysin®s, to combat resistant bacteria, commented Markus Matuschka v. Greiffenclau, CEO and co-founder of Lysando AG.

About SCG:

SCG, one of the leading conglomerates in the ASEAN region, comprises three core businesses: SCG Cement-Building Materials, SCG Chemicals, and SCG Paper. With more than 200 companies under its umbrella and approximately 50,000 employees, SCG creates and distributes innovative products and services that respond to the current and future needs of consumers.

About Lysando:

Lysando AG is a technology leader in the area of antimicrobial proteins. This new platform paves the way for the development of products specifically engineered to combat gram-negative and gram-positive bacteria for both antibiotic-resistant as well as persistent bacteria. Artilysin®s are an effective and environmentally friendly alternative to antibiotics.

CONTACT

WBCO Public Relations & Business Communications GmbH
Frank
Wöllstein
Tel.: +49 (0) 69 / 133 880 36
Fax: +49 (0) 69 / 133
880 33
Email: f.woellstein@wbco.de

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BRIC HOLDING Offers Aimedis – ICO: Germany’s Leading eHealth Platform Goes Public
  • Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and Head of Medical Research at SanBio Group, Published in Stroke
  • Clinigen signs agreement with Nordic Pharma for aprotinin
  • TDK株式会社:磁気ネックレス 「EXNAS(エクナス)D1」の発売について
  • 遠隔モニタリングと治療製品自動補充がPAP療法へのアドヒアランスを向上させることがレスメドの研究で示される